Valneva SE

Valneva SE is a specialty vaccine company registered in Saint-Herblain, France, developing, producing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States.

Filings

160 filings

All Inside information94 Voting rights and capital38 Earnings release12 Threshold crossing5 Quarterly financial information4 Half-year financial report3 Universal registration document2 Annual financial report2

03/09/2025
Valneva annonce de nouvelles données positives d’innocuité et d’immunogénicité de Phase 2 pour le candidat vaccin contre la maladie de Lyme
Inside informationFrench
25/08/2025
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
Inside informationFR
18/08/2025
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
Inside informationFR
12/08/2025
VALNEVA : Rapport Semestriel 2025
Half-year financial reportFrench
12/08/2025
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
Half-year financial reportFR
07/08/2025
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
Inside informationFR
05/08/2025
VALNEVA Declaration of shares and voting rights: July 31, 2025
Voting rights and capitalFR
11/07/2025
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly
Inside informationFR
03/07/2025
VALNEVA Declaration of shares and voting rights: June 30, 2025
Voting rights and capitalFR
26/06/2025
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
Inside informationFR
25/06/2025
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
Inside informationFR
05/06/2025
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
Inside informationFR
05/06/2025
[Valneva SE] Declaration of shares and voting rights - May 2025
Voting rights and capitalFR
04/06/2025
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
Inside informationFR
26/05/2025
Valneva to Participate at U.S. and European Investor Conferences in June
Inside informationFR
12/05/2025
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
Inside informationFR
07/05/2025
VALNEVA Declaration of shares and voting rights: April 30, 2025
Voting rights and capitalFR
07/05/2025
Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Quarterly financial informationFR
26/04/2025
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
Inside informationFR
18/04/2025
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
Inside informationFR
16/04/2025
Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®
Inside information
14/04/2025
Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country
Inside informationFR
09/04/2025
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
Inside informationFR
03/04/2025
Valneva SE Shareholding Declaration - March 2025
Voting rights and capitalFR
01/04/2025
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
Inside informationFR
31/03/2025
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
Inside informationFR
26/03/2025
Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program
Inside informationFR
25/03/2025
Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F
Annual financial reportFR
24/03/2025
Document d'enregistrement universel 2024
Universal registration documentFrenchZIP
24/03/2025
Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
Inside informationFR
20/03/2025
Valneva publie ses résultats financiers 2024 et fait un point sur son activité et ses perspectives financières
Inside informationFrench
20/03/2025
Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook
Earnings release
05/03/2025
VALNEVA Declaration of shares and voting rights: February 28, 2025
Voting rights and capitalFR
03/03/2025
Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
Inside informationFR
28/02/2025
Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ®
Inside informationFR
18/02/2025
Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook
Inside information
18/02/2025
Valneva publie son chiffre d’affaires et sa trésorerie non audités pour l’exercice 2024 et fournit des indications préliminaires pour l’exercice 2025
Earnings releaseFrench
06/02/2025
Shareholding declaration Valneva SE - January 2025
Voting rights and capitalFR
05/02/2025
Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ®
Inside informationFR
30/01/2025
Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32.8 Million
Inside informationFR
22/01/2025
Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision
Inside informationFR
20/01/2025
Valneva Reports High Sustained Immune Response in Adolescents One Year After Single Vaccination with its Chikungunya Vaccine
Inside informationFR
06/01/2025
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
Inside informationFR
03/01/2025
VALNEVA Declaration of shares and voting rights: December 31, 2024
Voting rights and capitalFR

About

ISIN: FR0004056851
Ticker: VLA
LEI: 969500DIVIP5VKNW4948
Sector: Health care
Founded: 1999
Country of registration: FR
Last filing: 22/07/2026, 17:45

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive